Bionano Genomics Reports 67% Jump in Optical Genome Mapping Studies at ESHG 2026
Event summary
- Bionano Genomics reported a 67% year-over-year increase in studies featuring Optical Genome Mapping (OGM) at the 2026 European Society of Human Genetics (ESHG) conference.
- The number of studies grew from 21 in 2025 to 35 in 2026, with authorship spanning 17 countries, up from 12 in 2025.
- Rare and constitutional genetic disorders were the largest research theme, representing roughly half of the studies.
- Europe contributed the most studies overall, while Brazil was the single largest national contributor.
- Studies featured OGM both on its own and alongside chromosomal microarray, classical karyotyping, and long- and short-read sequencing.
The big picture
Bionano Genomics' 67% increase in OGM studies at ESHG 2026 underscores the growing acceptance of its technology in the genomics field. The expansion into 17 countries and the focus on rare genetic disorders highlight the strategic shift towards more comprehensive structural variant detection. This trend aligns with the broader industry movement towards integrating advanced genomic technologies into clinical diagnostics, positioning Bionano at the forefront of the digital pathology revolution.
What we're watching
- Market Adoption
- The pace at which OGM is being integrated into clinical research and diagnostic workflows will determine its long-term market penetration.
- Technological Synergy
- Whether OGM can sustain its growth by effectively combining with sequencing technologies to offer comprehensive genomic solutions.
- Geographic Expansion
- How Bionano Genomics will leverage its growing international presence to drive further adoption in emerging markets.
Related topics